Stocks Health care RARE
NASDAQ · Health careUltragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. brought in $717M of revenue over the twelve months to June 30, 2026, up 17.5% from a year earlier. It posted a net loss of $586M. In fiscal 2025 capital spending exceeded operating cash flow by $472M. At June 30, 2026 it held $125M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Ultragenyx Pharmaceutical Inc. does
Ultragenyx Pharmaceutical Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RARE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $673M | -$575M | -$5.83 | -$472M |
| 2024 | $560M | -$569M | -$6.29 | -$421M |
| 2023 | $434M | -$607M | -$8.25 | -$519M |
| 2022 | $363.3M | -$707.4M | -$10.12 | -$496.6M |
| 2021 | $351.4M | -$454M | -$6.70 | -$411.8M |
| 2020 | $271M | -$186.6M | -$3.07 | -$176.1M |
Latest SEC filings
What Ultragenyx Pharmaceutical Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 17, 2026Other event 8-K
- September 2, 2026Other event 8-K
- August 19, 2026Other event 8-K
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 11, 2026Other event 8-K
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 4, 2026
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
Questions about RARE
What does Ultragenyx Pharmaceutical Inc. do?
Ultragenyx Pharmaceutical Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RARE.
Is Ultragenyx Pharmaceutical Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $586M on revenue of $717M.
How much revenue does Ultragenyx Pharmaceutical Inc. make?
Over the twelve months to June 30, 2026 Ultragenyx Pharmaceutical Inc. reported revenue of $717M. That is 17.5% more than a year earlier.
When did Ultragenyx Pharmaceutical Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 17, 2026.
Similar companies
Follow RARE
Get an email when Ultragenyx Pharmaceutical Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow RARE: get an email when it filesWhere the numbers come from
Financial figures are the values Ultragenyx Pharmaceutical Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.